NCT05375370 Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
| NCT ID | NCT05375370 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Rouen |
| Condition | Hepatocellular Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2022-08-04 |
| Primary Completion | 2029-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2022-08-04 with a primary completion date of 2029-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer. In order to meet this objective, this biomarker will be measured in your blood before and after surgery, at three and six months.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. HCC diagnosed on consensus radiological criteria in cirrhotic patients (EASL-EORTC 2012): helical CT or MRI with triple arterial, portal and late acquisition. The diagnosis is based on the presence of hypervascularization at the early arterial time (wash-in) with wash-out (hypodensity or hypointensity compared to non-tumor liver parenchyma) at the portal phase or late phase compared to non-tumor parenchyma. 3. HCC diagnosed histologically in the absence of a diagnosis on imaging (see IC n°2 above) 4. Patient operated on for liver resection or radiofrequency destruction 5. Treatment decision validated by the digestive oncology PCR 6. Patient having read and understood the information letter and signed the non-opposition form 7. Patient follow-up at the Charles Nicolle University Hospital in Rouen Exclusion Criteria: 1. Other active cancer or hematological malignancy 2. Contra-indication to surgery 3. Patient not affiliated to the social security system 4. Pregnant woman or parturient or breastfeeding 5. Person under court protection, sub guardianship or curatorship
Contact & Investigator
Edouard ROUSSEL, MD
PRINCIPAL INVESTIGATOR
University Hospital, Rouen
Frequently Asked Questions
Who can join the NCT05375370 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05375370 currently recruiting?
Yes, NCT05375370 is actively recruiting participants. Contact the research team at edouard.roussel@chu-rouen.fr for enrollment information.
Where is the NCT05375370 trial being conducted?
This trial is being conducted at Rouen, France.
Who is sponsoring the NCT05375370 clinical trial?
NCT05375370 is sponsored by University Hospital, Rouen. The principal investigator is Edouard ROUSSEL, MD at University Hospital, Rouen. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.